• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Hematopoietic Cell Transplant Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease
Sickle cell disease (SCD) is the most common inherited hemoglobin disorder affecting approximately 100,000 people in the United States (U.S.), a majority of whom are Black/African American, with an incidence rate of 1 in every 365 births.1 SCD is a chronic health condition associated with acute painful vaso-occlusive crisis (VOC), acute chest syndrome (ACS), stroke, chronic organ damage and culminates in a life expectancy that is less than half that of the general American population.2-4
Source: Biology of Blood and Marrow Transplantation - April 21, 2021 Category: Hematology Authors: Tatenda G. Mupfudze, Christa Meyer MS, Jaime M. Preussler, Lih-Wen Mau, Yung-Tsi Bolon, Patricia Steinert, Staci D. Arnold, Wael Saber, Lakshmanan Krishnamurti Source Type: research

Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease
Sickle cell disease (SCD) is the most common inherited hemoglobin disorder, affecting approximately 100,000 people in the United States, a majority of whom are Black/African American, with an incidence rate of 1 in every 365 births [1]. SCD is a chronic health condition associated with acute painful vaso-occlusive crisis (VOC), acute chest syndrome (ACS), stroke, and chronic organ damage and culminates in a life expectancy that is less than one-half that of the general American population [2 –4].
Source: Biology of Blood and Marrow Transplantation - April 21, 2021 Category: Hematology Authors: Tatenda G. Mupfudze, Christa Meyer, Jaime M. Preussler, Lih-Wen Mau, Yung-Tsi Bolon, Patricia Steinert, Staci D. Arnold, Wael Saber, Lakshmanan Krishnamurti Source Type: research

Allogenic Hematopoietic Stem Cell Transplantation in Sickle Cell Disease
Sickle cell disease (SCD) is one of the most common monogenic disorders worldwide and affects approximately 100,000 people in the United States alone. SCD can cause numerous complications, including anemia, pain, stroke, and organ failure, which can lead to death. Although there are a few disease-modifying treatments available to patients with SCD, the only current curative option is a hematopoietic stem cell transplant (HSCT). In this review, we will discuss the different approaches to allogeneic HSCT in the treatment of SCD and the outcomes of these approaches.
Source: Transfusion and Apheresis Science - January 10, 2021 Category: Hematology Authors: Dana K. Furstenau, John F. Tisdale Source Type: research

Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium
Sickle cell disease (SCD) is the most common inherited hemoglobinopathy, affecting nearly 100,000 individuals in the United States and approximately 300,000 worldwide, with low-income countries bearing the highest burden [1,2]. It is associated with several complications, including debilitating morbidity, organ injury, and shortened life expectancy. Progress in the overall management of SCD has been made in recent years, namely improved health maintenance surveillance programs, penicillin prophylaxis, chronic blood transfusions, vaccines, primary and secondary stroke prophylaxis, use of hydroxyurea, and approval of novel a...
Source: Biology of Blood and Marrow Transplantation - December 10, 2020 Category: Hematology Authors: Madiha Iqbal, Tea Reljic, Selim Corbacioglu, Josu de la Fuente, Eliane Gluckman, Ambuj Kumar, Farah Yassine, Ernesto Ayala, Areej El-Jawahri, Hemant Murthy, Fahad Almohareb, Shahrukh K. Hashmi, Barbara Cappelli, Ali Alahmari, Graziana Maria Scigliuolo, Ad Source Type: research

Systematic review/meta-analysis on efficacy of allogeneic HCT in sickle cell disease: an international effort on behalf of the Pediatric Diseases Working Party of EBMT and the Sickle Cell Transplantation International Consortium
Sickle cell disease (SCD) is the most common inherited hemoglobinopathy affecting nearly 100,000 individuals in the United States and approximately 300,000 worldwide, with low-income countries bearing the highest burden.1, 2 It is associated with several complications including debilitating morbidity, organ injury, and shortened life expectancy. Progress have been made in recent years to the overall management of SCD, namely improved health maintenance surveillance programs, penicillin prophylaxis, chronic blood transfusions, vaccines, primary and secondary stroke prophylaxis, use of hydroxyurea and approval of novel agent...
Source: Biology of Blood and Marrow Transplantation - December 10, 2020 Category: Hematology Authors: Madiha Iqbal, Tea Reljic, Selim Corbacioglu, Josu de la Fuente, Eliane Gluckman, Ambuj Kumar, Farah Yassine, Ernesto Ayala, Areej El-Jawahri, Hemant Murthy, Fahad Almohareb, Shahrukh K. Hashmi, Barbara Cappelli, Ali Alahmari, Graziana Maria Scigliuolo, Ad Source Type: research

Sickle Cell Disease Subjects Have a Distinct Abnormal Autonomic Phenotype Characterized by Peripheral Vasoconstriction With Blunted Cardiac Response to Head-Up Tilt
Conclusion We have shown that SCD subjects are much more likely than non-SCD subjects to have impaired cardiac, but intact peripheral responses to orthostatic stress induced by HUT. These abnormal responses are associated with low baseline cardiac parasympathetic activity, independent of hemoglobin level. The classification of autonomic phenotypes based on HUT response may have potential use for predicting disease severity, guiding and targeting treatments/interventions to alleviate the risk of adverse outcomes in SCD. Ethics Statement All experiments were conducted at Children’s Hospital Los Angeles (CHLA). The ...
Source: Frontiers in Physiology - April 10, 2019 Category: Physiology Source Type: research

Outcomes of Hospitalization for Stem Cell Transplant in Sickle Cell Disease: Are We There Yet?
Conclusions: The rate of inpatient mortality with SCT in sickle cell disease is lower than the overall inpatient mortality rate for allogeneic SCT (7%; Godara et al bbmt 2018), indicating a favorable outcome for these patients. Infections do occur commonly during the course of hospitalization, especially in association with GVHD. Length of stay is adversely impacted by occurrence of GVHD, bacterial sepsis, C.difficile infection and viral infections. While we are limited by duration of follow up in our study, these patterns suggest some essential modifiers for inpatient morbidity and mortality, therefore require validation ...
Source: Blood - November 21, 2018 Category: Hematology Authors: Godara, A., Siddiqui, N., Afzal, A., Khan, M., Yared, J., Kansagra, A., Dahiya, S. Tags: 732. Clinical Allogeneic Transplantation: Results: Poster III Source Type: research

Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease
Sickle cell disease (SCD) is a hemoglobinopathy affecting 1 in every 500 African American newborns and an estimated 100,000 persons in the United States [1]. Vascular occlusion caused by the sickled RBCs leads to decreased perfusion in target organs and manifests clinically as vaso-occlusive pain crisis, stroke (cerebral infarction), pulmonary restrictive disease, and pulmonary hypertension [2]. Despite advances in supportive care, including the use of hydroxyurea (HU), RBC transfusion, and iron chelation therapy, patients with SCD continue to experience considerable morbidity and mortality in their lifetime.
Source: Biology of Blood and Marrow Transplantation - October 20, 2017 Category: Hematology Authors: Hemalatha G. Rangarajan, Rolla Abu-Arja, Vinita Pai, Gregory M.T. Guilcher, Sandeep Soni Source Type: research

Outcomes of Unrelated Donor Stem Cell Transplant with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease
Sickle cell disease (SCD) is a hemoglobinopathy affecting 1 in every 500 African American newborns and an estimated 100,000 persons in the United States [1]. Vascular occlusion caused by the sickled RBCs leads to decreased perfusion in target organs and manifests clinically as vaso-occlusive pain crisis, stroke (cerebral infarction), pulmonary restrictive disease, and pulmonary hypertension [2]. Despite advances in supportive care, including the use of hydroxyurea (HU), RBC transfusion, and iron chelation therapy, patients with SCD continue to experience considerable morbidity and mortality in their lifetime.
Source: Biology of Blood and Marrow Transplantation - October 20, 2017 Category: Hematology Authors: Hemalatha G. Rangarajan, Rolla Abu-Arja, Vinita Pai, Gregory M.T. Guilcher, Sandeep Soni Source Type: research